

Figure S1. Strain differences in PRDX6 modification and total protein carbonylation in C3H and C57BL livers. (A) 2D gel electrophoresis and immunoblotting of PRDX6 in C3H and C57BL mouse livers under basal (-DDC) conditions and after DDC treatment. Note the increased intensity of the acidic PRDX6 isoforms in C57BL livers after DDC exposure. The numbers denote different charged isoforms of PRDX6. IEF, isoelectric focusing. (B) Quantification of total carbonylated protein in the livers of C 3 H and C 57 BL control and DDC-treated mice based on dinitrophenylhydrazine reactivity with protein carbonyl groups. ***, P < 0.001 using a two-way analysis of variance. Each tested group included three to four mice, and samples were analyzed in triplicates. Results are represented as the mean and the SD.


Figure S2. Strain comparison of Cyp2e1 levels, ductal proliferation, and glutathione levels. (A) Total Cyp2e1 and K19 (ductal marker) protein levels (left) and quantification of K19 band intensities (right). Coomassie stain serves as a loading control. (B) Relative mRNA expression for Cyp2e1 in C3H and C57BL livers before and after DDC treatment. (C) Liver levels of total and oxidized glutathione were quantified by an enzymatic recycling method using glutathione reductase, as described in Materials and methods. **, $\mathrm{P}<0.01$ using a two-way analysis of variance. Each tested group included three to four mice, and samples were analyzed in triplicates. Results are represented as the mean and the SD.

B Control siRNA/Untreated $\quad \square$ GAPDH siRNA/Untreated
$\square$ Control siRNAVehicle $\quad \square$ GAPDH siRNAVehicle
$\square$ Control siRNADDC $\quad \square$ GAPDH siRNA/DDC


Figure S3. Quantification of the immunoblotting data shown in Fig. 7. (A and B) The relative band densities were estimated using Photoshop CS2 software. Data are representative of three experimental repeats.

Table S1. Relative mRNA expression of selected genes in untreated and DDC-treated C3H and C57BL mice

| Gene | C3H |  | C57BL |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Control | DDC | Control | DDC |
| CBR3 | $1.19 \pm 0.177$ | $16.6 \pm 5.65$ | $1.71 \pm 0.619$ | $38.1 \pm 14.6^{a, b}$ |
| GSTA3 | $1.31 \pm 0.297$ | $1.34 \pm 0.085$ | $1.07 \pm 0.258$ | $1.23 \pm 0.338$ |
| GSTM 1 | $2.04 \pm 0.906$ | $16.8 \pm 2.53^{\text {c }}$ | $1.02 \pm 0.137$ | $5.93 \pm 2.34^{\mathrm{ar}, \mathrm{d}}$ |
| GSTP 1 | $1.13 \pm 0.197$ | $1.80 \pm 0.215^{\circ}$ | $0.990 \pm 0.045$ | $1.10 \pm 0.267^{\text {e }}$ |
| GSTP2 | $1.49 \pm 0.506$ | $29.3 \pm 14.6^{\text {f }}$ | $2.64 \pm 2.63$ | $10.2 \pm 3.10$ |
| PRDX6 | $1.42 \pm 0.361$ | $1.60 \pm 0.259$ | $1.09 \pm 0.257$ | $1.00 \pm 0.208$ |
| CA3 | $1.52 \pm 0.450$ | $0.370 \pm 0.121^{\ddagger}$ | $1.08 \pm 0.421$ | $0.210 \pm 0.020^{\circ}$ |
| GAPDH | $1.43 \pm 0.373$ | $2.46 \pm 0.172^{f}$ | $0.850 \pm 0.161$ | $0.697 \pm 0.151^{\text {d }}$ |
| NDPK-A | $1.41 \pm 0.354$ | $2.45 \pm 0.284$ | $1.01 \pm 0.012$ | $1.03 \pm 0.317$ |
| NDPK-B | $1.27 \pm 0.228$ | $1.46 \pm 0.179$ | $0.943 \pm 0.191$ | $1.18 \pm 0.327$ |
| PSMC6 | $1.77 \pm 0.738$ | $2.42 \pm 0.058$ | $0.833 \pm 0.145$ | $0.630 \pm 0.181^{\text {b }}$ |
| SBP 1 | $1.62 \pm 0.566$ | $2.71 \pm 0.223$ | $1.24 \pm 0.442$ | $1.43 \pm 0.592^{\text {e }}$ |

One-way analysis of variance and Tukey's multiple comparison tests were used.
${ }^{a} P<0.05$, relative to control group of the same strain.
${ }^{\mathrm{b}} \mathrm{P}<0.01$, relative to C 3 H in the same treatment group.
${ }^{\mathrm{c} P}<0.001$, relative to control group of the same strain.
${ }^{d} \mathrm{P}<0.001$, relative to C 3 H in the same treatment group.
${ }^{e P}<0.05$, relative to C 3 H in the same treatment group.
${ }^{f} P<0.01$, relative to control group of the same strain.

Table S2. Primers used for quantitative real-time PCR

| Gene | Primer sequence |
| :---: | :---: |
| NME1 or NDPK-A |  |
| Forward | 5'-GGACCTTCTCAAGGAGCACTAC-3' |
| Reverse | 5'-ACCACAAGCTGATCTCCTTCTC-3' |
| NME2 or NDPK-B |  |
| Forward | 5'-TCTGAAGAACACCTGAAGCAGC-3' |
| Reverse | 5'-TAGTCGATCAGTTCTTCGGG-3' |
| CA3 |  |
| Forward | 5'-GCTCTGCTAAGACCATCC-3' |
| Reverse | 5'-ATTGGCGAAGTCGGTAGG-3' |
| PRDX6 |  |
| Forward | 5'-TTGATGATAAGGGCAGGGAC-3' |
| Reverse | 5'-CTACCATCACGCTCTCTCCC-3' |
| CBR3 |  |
| Forward | 5'-TACTTGGCTCTCCTGCCTCC-3' |
| Reverse | 5'-GACTAGCTGGCCGTGAGGTT-3' |
| SELENBP1 |  |
| Forward | 5'-GTGCAACGTGAGCAGTTT-3' |
| Reverse | 5'-CTGCATCCCCAGGCTTCT-3' |
| PSMC6 |  |
| Forward | 5'-CGGGTGAAAGTGCTCGTTTG-3' |
| Reverse | 5'-AGCAAAGCAGGATCCAGTGT-3' |
| GSTA3 |  |
| Forward | 5'-TGGACAACTTCCCTCTCCTGAA-3' |
| Reverse | 5'-AATCTTCTTTGCTGACTCAACACATT-3' |
| GSTM 1 |  |
| Forward | 5'-CCTATGATACTGGGATACTGGAACG-3' |
| Reverse | 5'-GGAGCGTCACCCATGGTG-3' |
| GSTP1 |  |
| Forward | 5'-GCAAATATGTCACCCTCATCTACACC-3' |
| Reverse | 5'-GCAGGGTCTCAAAAGGCTTCA-3' |
| GSTP2 |  |
| Forward | 5'-CAAATATGGCACCATGATCTACAGA-3' |
| Reverse | 5'-GCAGGGTCTCAAAAGGCTTCA-3' |
| GAPDH |  |
| Forward | 5'-TCCACCACCCTGTTGCTGTAG-3' |
| Reverse | 5'-GACCACAGTCCATGACATCACT-3' |
| 185 |  |
| Forward | 5'-ACCTGGTTGATCCTGCCAGTAG-3' |
| Reverse | 5'-TTAATGAGCCATTCGCAGTTTC-3' |

